Cargando…

Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study

BACKGROUND: Immunotherapy plus chemotherapy have been confirmed to be effective in treating advanced or metastatic gastric cancer (GC). Anti- programmed death-1 (PD-1) plus antiangiogenic agents have shown promising activity and tolerant toxicity in subsequent therapy of late-stage gastric cancer. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Tongpeng, Wang, Wenjie, Bao, Ruikang, Xia, Xihua, Zhang, Junling, Huang, Mengli, Chen, Xiaofeng, Wang, Rong, Zhang, Hao, Liu, Xisheng, Li, Qiong, Shu, Yongqian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007938/ https://www.ncbi.nlm.nih.gov/pubmed/36915465 http://dx.doi.org/10.21037/jgo-23-73

Ejemplares similares

The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
por: Wang, Xinwei, et al.
Publicado: (2022)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Peng, Ye, et al.
Publicado: (2021)

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study
por: Yang, Guangjian, et al.
Publicado: (2022)

JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients
por: Qian, Jing, et al.
Publicado: (2016)

Efficacy of intra-arterial chemotherapy with sequential anti-PD-1 antibody in unresectable gastric cancer: A retrospective real-world study
por: Xiang, Xiaosong, et al.
Publicado: (2023)

JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells
por: Ma, Ling, et al.
Publicado: (2016)

Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma
por: Wang, Chao, et al.
Publicado: (2020)

Self-anti-angiogenesis nanoparticles enhance anti-metastatic-tumor efficacy of chemotherapeutics
por: Luo, Jiamao, et al.
Publicado: (2021)

Anti-angiogenesis is anti-actin
por: Sreenivasan, Aparna
Publicado: (2004)

Neoantigen personalized vaccine plus anti-PD-1 antibody in cancer patients
por: González-Cao, María, et al.
Publicado: (2022)

Radiotherapy plus anti-PD1 versus radiotherapy for hepatic toxicity in patients with hepatocellular carcinoma
por: Zhang, Rui-Jun, et al.
Publicado: (2023)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)

Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
por: Liu, Qingyan, et al.
Publicado: (2023)

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
por: Gu, Lihu, et al.
Publicado: (2019)

HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities
por: Chu, Wendi, et al.
Publicado: (2022)

High endothelial venules predict response to PD-1 inhibitors combined with anti-angiogenesis therapy in NSCLC
por: Ye, Dafu, et al.
Publicado: (2023)

A contrast-enhanced ultrasound-based nomogram for the prediction of therapeutic efficiency of anti-PD-1 plus anti-VEGF agents in advanced hepatocellular carcinoma patients
por: Sun, Chao, et al.
Publicado: (2023)

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
por: Aitelhaj, Meryem, et al.
Publicado: (2016)

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
por: Chen, Jiming, et al.
Publicado: (2022)

Apoptotic Induction of Mitochondria-Anchored Aggregation-Induced Emission Luminogens through the Intrinsic Mitochondrial Pathway
por: Zhang, Hao, et al.
Publicado: (2022)

Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report
por: Zheng, Yue, et al.
Publicado: (2023)

Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma
por: Zhou, Xiang, et al.
Publicado: (2020)

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
por: Wagner, Nikolaus B, et al.
Publicado: (2018)

Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease
por: Wu, Florence T. H., et al.
Publicado: (2018)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
por: Qi, Yihang, et al.
Publicado: (2021)

Rare Combined Small Cell Lung Carcinoma and Lung Squamous Cell Carcinoma Response to PD-1 Inhibitor as Third-Line Therapy: A Case Report
por: Liu, Zhisheng, et al.
Publicado: (2023)

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
por: Alden, Stephanie L., et al.
Publicado: (2023)

Angiogenesis, Anti-Tumor, and Anti-Metastatic Activity of Novel α-Substituted Hetero-Aromatic Chalcone Hybrids as Inhibitors of Microtubule Polymerization
por: Sun, Moran, et al.
Publicado: (2021)

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
por: Zhao, Zihan, et al.
Publicado: (2023)

Knockdown of EphB3 inhibits cell proliferation partly through the AKT signaling pathway and represses epithelial-mesenchymal transition in esophageal squamous cell carcinoma
por: Tang, Luqun, et al.
Publicado: (2022)

Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
por: Chang, Xiujuan, et al.
Publicado: (2023)

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
por: de Azambuja, E., et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
por: Yu, Bingran, et al.
Publicado: (2023)

Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel PTH2R-ALK Fusion Lung Adenocarcinoma: A Case Report
por: Shen, Gang, et al.
Publicado: (2021)

Anti-angiogenesis and anti-metastasis effects of Polyphyllin VII on Hepatocellular carcinoma cells in vitro and in vivo
por: Zhang, Chao, et al.
Publicado: (2021)

Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)
por: Nakamura, Y., et al.
Publicado: (2021)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study
por: Liao, Guixiang, et al.
Publicado: (2021)

Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer
por: Siddiqui, Bilal A., et al.
Publicado: (2022)

Analyzing the Chinese landscape in anti-diabetic drug research: leading knowledge production institutions and thematic communities
por: Deng, Junling, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_i5vj5km0npjh97o94i3foefpup